Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Stopped The study experienced lower accrual rates after the onset of COVID. Upon review of the collected data it was deemed that an adequate amount of subjects has been enrolled to date to assess study aims.
Conditions
- Acute Biphenotypic Leukemia
- Acute Erythroid Leukemia in Remission
- Acute Leukemia in Remission
- Acute Lymphoblastic Leukemia in Remission
- Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome
- Acute Myeloid Leukemia in Remission
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1
- Acute Myeloid Leukemia With Multilineage Dysplasia
- Acute Myeloid Leukemia With t(6;9)
- Acute Undifferentiated Leukemia
- Adult Acute Lymphoblastic Leukemia in Complete Remission
- B Acute Lymphoblastic Leukemia With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1)
- Ph+ ALL
- Burkitt Lymphoma
- Childhood Acute Lymphoblastic Leukemia in Complete Remission
- DS Stage II Plasma Cell Myeloma
- DS Stage III Plasma Cell Myeloma
- Myelodysplastic Syndrome
- Recurrent Anaplastic Large Cell Lymphoma
- Blasts Under 5 Percent of Bone Marrow Nucleated Cells
- Recurrent Follicular Lymphoma
- Recurrent Hodgkin Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Secondary Acute Myeloid Leukemia
- T Lymphoblastic Lymphoma
- Hematopoietic Cell Transplant Recipient
Interventions
- DRUG: Cyclophosphamide
- BIOLOGICAL: Filgrastim
- DRUG: Fludarabine Phosphate
- DRUG: Mycophenolate Mofetil
- PROCEDURE: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
- PROCEDURE: Peripheral Blood Stem Cell Transplantation
- DRUG: Tacrolimus
- RADIATION: Total-Body Irradiation
Sponsor
Fred Hutchinson Cancer Center